Effects of neridronic acid on osteoclasts derived by physiological dual-cell cultures

Acta Histochemica

Volumn 109, Issue 5, 2007, Pages 397-402

  Nicolin, Vanessa ^a   Bareggi, Renato ^a   Baldini, Giovanna ^a   Bortul, Roberta ^a   Martinelli, Bruno ^a   Narducci, Paola ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Actin; Bisphosphonates; Co culture; Neridronic acid; Osteoclasts; Ultrastructure

Indexed keywords

BIOASSAY; CELL CULTURE; METABOLISM; PHYSIOLOGY; TUMORS;

BISPHOSPHONATES; NERIDRONIC ACID; OSTEOCLASTS; ULTRASTRUCTURE;

CARBOXYLIC ACIDS;

ACID PHOSPHATASE; ACTIN; BISPHOSPHONIC ACID DERIVATIVE; NERIDRONIC ACID; TARTARIC ACID;

ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; BONE TURNOVER; CELL CULTURE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PROTEIN LOCALIZATION; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

MURINAE;

EID: 34848885428     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2007.04.002     Document Type: Article

References (13)

1. Bab I.A., and Eithorn T.A. Polypeptide factors regulating osteogenesis and bone marrow repair. J Cell Biochem 158 (1994) 247-257
2. Body J.J., Burckhardt P., Delmas P.D., Diel I.J., Fleisch H., Kanis J.A., et al. Current use of bisphosphonates in oncology. J Clin Oncol 16 (1998) 3890-3899
3. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
4. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 19 (1998) 80-100
5. Husheem M., Nyman J.K., Vaaraniemi J., Vaananen H.K., and Hentunen T.A. Characterization of circulating human osteoclast progenitors: development of in vitro resorption assay. Calcif Tissue Int 76 (2005) 222-230
6. Nicolin V., Bareggi R., and Narducci P. Immunolocalization protein kinase C alpha, delta, epsilon zeta during pre-osteoclast differentiation induced by NfKB ligand and macrophage stimulating factor. J Histotech 29 (2006) 167-170
7. Nicolin V., Baldini G., Bareggi R., Zweyer M., Zauli G., Vaccarezza M., et al. Morphological features of osteoclasts derived from a co-culture system. J Mol Histol 37 (2006) 171-177
8. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonen J., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (2000) 2961-2978
9. Santini U., Gentilucci V., Vincenzi B., Picardi A., Vasaturo F., La Cesa A., et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14 (2003) 1468-1476
10. Shinoda H., Adamek G., Felix R., Fleisch H., Shenk R., Hagan P., et al. Structure-activity relationship of various bisphosphonates. Calcif Tissue Int 35 (1983) 87-99
11. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., and Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumour necrosis factor receptor and ligand families. Endocr Rev 20 (1999) 345-357
12. Veseley P., Boyde A., and Jones S.J. Behaviour of osteoclasts in vitro: contact behaviour of osteoclasts with osteoblast-like cells and networking of osteoclasts for 3D orientation. J Anat 181 (1992) 277-291
13. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC 3rd, Yanover MJ, et al. Intermittent cyclical ethidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.